Hims & Hers Health, Inc. (NYSE:HIMS) Shares Purchased by State Street Corp

State Street Corp increased its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 4.7% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 4,626,543 shares of the company’s stock after acquiring an additional 206,078 shares during the period. State Street Corp owned approximately 2.15% of Hims & Hers Health worth $85,221,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Nisa Investment Advisors LLC lifted its position in Hims & Hers Health by 679.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after acquiring an additional 1,603 shares in the last quarter. Quest Partners LLC lifted its position in Hims & Hers Health by 5,944.1% during the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock worth $72,000 after acquiring an additional 3,507 shares in the last quarter. Van ECK Associates Corp acquired a new position in Hims & Hers Health during the 2nd quarter worth approximately $111,000. CWM LLC lifted its position in Hims & Hers Health by 21.4% during the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after acquiring an additional 1,054 shares in the last quarter. Finally, Quarry LP lifted its position in Hims & Hers Health by 91.0% during the 3rd quarter. Quarry LP now owns 6,113 shares of the company’s stock worth $113,000 after acquiring an additional 2,913 shares in the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

Hims & Hers Health Price Performance

Shares of HIMS opened at $31.24 on Tuesday. The company has a market cap of $6.82 billion, a P/E ratio of 70.99 and a beta of 1.25. The stock has a fifty day moving average price of $25.02 and a 200 day moving average price of $21.06. Hims & Hers Health, Inc. has a 12 month low of $8.09 and a 12 month high of $35.02.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. The firm had revenue of $401.56 million during the quarter, compared to the consensus estimate of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm’s revenue was up 77.1% on a year-over-year basis. During the same period in the prior year, the business earned ($0.04) EPS. As a group, research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on HIMS. TD Cowen reaffirmed a “buy” rating and issued a $28.00 target price on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft upped their target price on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research report on Wednesday, November 6th. Needham & Company LLC began coverage on Hims & Hers Health in a research report on Thursday, August 22nd. They issued a “buy” rating and a $24.00 target price on the stock. Bank of America lowered Hims & Hers Health from a “buy” rating to an “underperform” rating and cut their target price for the company from $32.00 to $18.00 in a research report on Thursday, November 14th. Finally, Canaccord Genuity Group upped their target price on Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a research report on Monday, December 2nd. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $21.43.

Insider Transactions at Hims & Hers Health

In other news, CEO Andrew Dudum sold 45,767 shares of the company’s stock in a transaction on Friday, September 20th. The stock was sold at an average price of $16.33, for a total value of $747,375.11. Following the completion of the sale, the chief executive officer now owns 67,015 shares in the company, valued at $1,094,354.95. This represents a 40.58 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Michael Chi sold 7,259 shares of the company’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $32.25, for a total value of $234,102.75. Following the completion of the sale, the insider now owns 184,947 shares of the company’s stock, valued at approximately $5,964,540.75. This trade represents a 3.78 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,064,976 shares of company stock valued at $25,396,895. 17.71% of the stock is currently owned by corporate insiders.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.